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Prognostic role of traditional cardiovascular risk 
factors in patients with idiopathic pulmonary arterial 
hypertension
Kamil Jonas1, Marcin Waligóra1, Wojciech Magoń1, Tomasz Zdrojewski2,3, Jakub Stokwiszewski3, 
Wojciech Płazak1, Piotr Podolec1, Grzegorz Kopeć1
A b s t r a c t
Introduction: Metabolic alterations have been recently associated with on-
set and progression of idiopathic pulmonary arterial hypertension (IPAH). 
We aimed to determine the prevalence and prognostic role of cardiovascular 
risk factors in patients with IPAH.
Material and methods: Between February 2009 and January 2015 we re-
cruited consecutive IPAH patients. Clinical assessment included medical his-
tory, fasting glucose, lipid profile, N-terminal pro-brain natriuretic peptide 
concentration, 6-minute walk test distance, WHO functional class and he-
modynamic evaluation. Patients’ risk was estimated based on the Swedish 
PAH Register grading system.
Results: The study group included 61 IPAH patients, and the control group 
included 2413 Polish residents. When compared to the general population, 
IPAH patients had lower low-density lipoprotein cholesterol (LDL-C) and 
a higher triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ra-
tio. Female patients were characterized by elevated glucose level, higher 
prevalence of diabetes and lower HDL-C than controls. PAH severity grade 
correlated positively with age and TG/HDL-C ratio (R = 0.29, p = 0.02) and 
inversely with LDL-C (R = –0.28, p = 0.03) and HDL-C (R = –0.39, p = 0.02) 
concentrations. After a  follow-up of 48 (23–79) months we recorded 28 
deaths in the IPAH group. In the regression analysis lower LDL-C (p = 0.002) 
and HDL-C (p = 0.0002) levels, and higher TG/HDL-C ratio (p = 0.003) and 
glucose level (p = 0.003) were associated with all-cause mortality after ad-
justment for age, sex or PAH severity grade.
Conclusions: Patients with IPAH are characterized by an altered profile of 
lipid and glucose metabolism. Lowered levels of LDL-C and HDL-C and in-
creased TG/HDL-C ratio correlate with disease severity and together with 
elevated plasma glucose level predict poor survival in IPAH.
Key words: pulmonary hypertension, risk assessment, lipid metabolism.
Introduction
Pulmonary arterial hypertension (PAH) is a progressive and incurable 
disease caused by uncontrolled hyperplasia of small pulmonary arter-
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ies. The European Society of Cardiology (ESC) 
proposed a  set of prognostic factors including 
laboratory, clinical, imaging and hemodynamic pa-
rameters to stratify the risk of death in 1 year [1].
Recent experimental and clinical studies 
demonstrated the association between severity 
of pulmonary vascular disease and a  spectrum 
of metabolic alterations [2–4]. Decreased levels 
of high-density lipoprotein cholesterol (HDL-C) 
were observed in subjects with PAH and were 
associated with worse clinical outcomes [5]. An 
increased triglyceride to HDL-C (TG/HDL-C) ratio 
was also found to be more prevalent in females 
with PAH than in healthy subjects and was pro-
posed as a novel risk factor in this population [6, 
7]. Patients with PAH are also more often charac-
terized by glucose intolerance [8, 9]. The clinical 
significance of some other traditional cardiovas-
cular disease (CVD) risk factors in patients with 
PAH may differ from the general population. In our 
recent study in a sample of 140 PAH males and fe-
males low-density lipoprotein cholesterol (LDL-C) 
level was lower than in age-matched controls and 
was associated with higher mortality [10]. What 
is more, in patients with pulmonary hypertension, 
similarly to other populations with severe chronic 
diseases, obesity was found to correlate with bet-
ter survival [11]. 
Current knowledge about the significance of 
classical CVD risk factors in prognosis of patients 
with idiopathic PAH (IPAH) is however scarce and 
based only on single reports with a relatively short 
observation period. In most of them the PAH pop-
ulations were heterogeneous and included pa-
tients with connective tissue disease, which itself 
may affect CVD risk status.
Therefore in the present study we aimed to 
determine the prevalence of traditional CVD risk 
factors in the population of patients with IPAH as 
compared to the general population and to assess 
their prognostic role. We also evaluated the rela-
tionship between CVD risk factors and severity of 
IPAH using a  recently validated comprehensive 
risk assessment tool.
Material and methods 
Patient population
We prospectively recruited consecutive IPAH 
patients from a  single pulmonary hypertension 
reference center between February 2009 and 
January 2015. Eligible patients had pre-capillary 
pulmonary hypertension with pulmonary vascu-
lar resistance > 3 Wood units in the absence of 
other causes of pre-capillary pulmonary hyperten-
sion [1]. The only absolute contraindication was 
a lack of informed consent; the relative contrain-
dications were active infection and hemodynam-
ic instability. The control group was chosen from 
the NATPOL 2011 study designed to analyze the 
prevalence of CVD risk factors in the Polish po- 
pulation [12].
Follow-up
All-cause mortality of IPAH patients was as-
sessed using reports of the Department of Na-
tionals’ and Foreigners’ Affairs and telephone in-
terviews. We observed the patients from the time 
of the first clinical assessment in our center until 
April 2018. The local ethics committee revised and 
approved the study protocol which conforms to 
the guidelines of the Declaration of Helsinki. Pri-
or to the study enrollment, we collected informed 
consent from each participant.
Evaluation of IPAH patients
Clinical evaluation, laboratory tests and as-
sessment of hemodynamic parameters were 
made during the first assessment of patients 
in our department. We collected demographic 
data and relevant medical history including use 
of lipid-lowering drugs such as statin, niacin, fi-
brate and estrogen replacement therapy. Diabe-
tes, hypertension, overweight (body mass index; 
BMI ≥ 25 kg/m2) and obesity (BMI ≥ 30 kg/m2) 
were diagnosed based on current guidelines 
[13–15]. We measured arterial blood pressure 
(BP) and N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) concentration and assessed 
6-minute walk test distance (6-MWD) and WHO 
functional class (WHO-FC). Active smoking was 
defined as smoking for one month or more in the 
previous year [16]. We collected venous blood 
from each participant after 12 h of fasting on the 
day of hemodynamic assessment. Complete lipid 
profile was assessed using the direct colorimetric 
method as described previously [10]. Right heart 
catheterization was performed using a  Swan-
Ganz catheter. We calculated cardiac output with 
the oxygen consumption method [17]. Methods 
of clinical and laboratory assessment of the con-
trols from the NATPOL study were described pre-
viously [12].
PAH severity grade
Patients’ baseline risk was estimated based 
on the Swedish PAH Register (SPAHR) grading 
system [18]. The following variables were as-
signed 1, 2 or 3 points according to the cut-off 
values for low, intermediate and high risk, avail-
able in the risk assessment method of the ESC 
guidelines: WHO-FC, 6-MWD, NT-proBNP, area of 
the right atrium, right atrial pressure, presence 
of pericardial effusion, cardiac index, and mixed 
venous oxygen saturation [1]. A  mean PAH se-
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verity grade for every patient was calculated by 
dividing the sum of all grades by the number of 
assessed variables and then was rounded off to 
the nearest integer to assign patients to specific 
risk groups [18]. 
Statistical analysis
We used mean ± standard deviation to present 
continuous variables and counts (%) for categori-
cal variables. Comparison of continuous variables 
between groups was performed using Student’s 
t-test or the Mann-Whitney U-test, according to 
data distribution. Comparison of categorical vari-
ables was performed using the c2 test. For the 
comparison between control and study groups, 
males and females were separately matched for 
age. To assess the relationship between CVD risk 
factors and all-cause mortality, we used Cox pro-
portional hazards regression. Models were adjust-
ed for age and/or sex and established markers of 
disease severity (PAH severity grade). The alpha 
level was set as 0.05. Statistical analysis was per-
formed using Dell Inc. (2016), Dell Statistica (data 
analysis software system), version 13. software.
dell.com and MedCalc Statistical Software version 
18.6 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2018).
Results
Study population
Between February 2009 and January 2015 we 
recruited 61 consecutive IPAH patients (all eligible 
subjects) of whom most (87%) were diagnosed 
for the first time and did not receive PAH-spe-
cific therapies. Other patients were treated with 
PAH-targeted drugs: 3 (5%) were receiving silde-
nafil in monotherapy, 3 (5%) were treated with 
bosentan, 1 patient was treated with a prostacy-
clin analogue and 1 with dual combination ther-
apy (sildenafil and bosentan). In every patient 
PAH-specific treatment was initiated immediately 
after making a diagnosis during the first hospital-
ization of a patient in our center. Our study did not 
have any effect on the therapeutic decisions made 
in our patients. At the end of the observation pe-
riod 26 (42.5%) patients were treated with mono-
therapy with PAH-specific drug (8 with sildenafil, 
6 with bosentan, 6 with prostacyclin analogue and 
6 with calcium channel blocker), 26 (42.5%) with 
dual and 9 (15%) with triple combination therapy 
with sildenafil, bosentan and prostacyclin ana-
logue. A group of 34 (56%) patients were treated 
with parenteral prostacyclin analogues. Charac-
teristics of study patients are shown in Table I. 
The control group included 1168 male and 1245 
female Polish residents aged 42.9 ±24 and 44.8 
±27.1 years, respectively. 
Prevalence of CVD risk factors in IPAH 
patients
We identified diabetes in 10 (17%) individuals, 
hypertension in 23 (38%), overweight in 21 (34%) 
and obesity in 8 (13%) patients. Three (5%) pa-
tients were classified as smokers. At enrollment 
18 (30%) patients used statins; none of the pa-
tients was treated with niacin, fibrate or estrogen 
replacement therapy. Chronic kidney disease was 
diagnosed in 9 (15%) IPAH patients. Nine (15%) 
patients were previously diagnosed with coronary 
artery disease, 1 patient had myocardial infarc-
tion, 2 patients were diagnosed with peripheral 
artery disease and there were no cases of stroke 
in this group. Daily activities of study patients 
were significantly limited as the majority of them 
were in the WHO-FC III (42, 69%) or IV (14, 23%). 
At first evaluation all patients were recommended 
to avoid excessive physical activity that leads to 
distressing symptoms and were not advised to fol-
low any specific dietary recommendations.
Comparison of the prevalence of CVD risk 
factors in IPAH males and females  
and age-matched controls
When compared to the general population, 
IPAH patients had lower LDL-C and a higher TG/
HDL-C ratio. What is more, only female patients 
were characterized by elevated glucose level, 
Table I. Characteristics of the study group (IPAH 
patients, n = 61)
Parameter Value
Age [years] 50.0 ±17.1
Female sex, n (%) 40 (66%)
WHO-FC, n (%):
II 5 (8)
III 42 (69)
IV 14 (23)
NT-proBNP [pg/ml] 2405.0 ±3370.9
6-MWD [m] 336.3 ±117
CI [l/min/m2] 1.86 ±0.59
RAP [mm Hg] 8.0 ±5.2
mPAP [mm Hg] 51.2 ±18.2
PVR [WU] 15.3 ±9.7
SvO2 (%) 57.8 ±11.4
6-MWD – 6-minute walk distance, CI – cardiac index, IPAH – 
idiopathic pulmonary arterial hypertension, NT-proBNP – N-terminal 
pro-brain natriuretic peptide, mPAP – mean pulmonary artery 
pressure, PVR – pulmonary vascular resistance, RAP – right atrial 
pressure, SvO
2
 – mixed venous oxygen saturation, WHO-FC – WHO 
functional class.
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higher prevalence of diabetes and lower HDL-C 
than controls. In our group 22 (36%) patients had 
diabetes or used statins. When only patients not 
using statins were analyzed (n = 43) they were 
still characterized by significantly lower LDL-C 
(2.79 ±0.8 in females and 2.31 ±0.94 mmol/l in 
males) than control patients who did not use 
statins (3.3 ±1.1  mmol/l, p = 0.02 for females, 
3.3 ±1.2 mmol/l, p = 0.01 for males). Similarly, 
when females without diabetes (n = 32) were 
analyzed they were characterized by higher glu-
cose (5.4 ±0.72 mmol/l) and TG/HDL-C (2.4 ±1.3) 
concentrations than female controls without di-
abetes (4.9 ±0.8 mmol/l, p < 0.001 and 2.0 ±1.7, 
p = 0.01 for glucose and TG/HDL, respectively). 
We found no differences in HDL-C concentration 
between females with and without diabetes 
(1.32 ±0.4 vs. 1.32 ±0.4 mmol/l, p = 0.9). There 
were no differences in BMI and TG concentra-
tion between patients and controls. Comparison 
of CVD risk factors between IPAH males and 
females and the age-matched control group is 
shown in Table II.
CVD risk factors in prediction of mortality 
in IPAH patients
After a  median follow-up time of 48 (23–79) 
months we recorded 28 deaths in the IPAH group. 
In the univariable analysis we found that low-
er LDL-C and HDL-C levels, and higher TG/HDL-C 
ratio and glucose level were associated with all-
cause mortality. All these metabolic parameters 
remained significant in prediction of mortality 
after adjusting for age, or age and sex or PAH se-
verity grade. In Cox regression analysis statin use 
(p = 0.23) and presence of diabetes (p = 0.18) 
were not significant factors affecting patients’ 
prognosis. Details of Cox regression analysis are 
shown in Table III.
PAH severity grade
The median PAH severity grade in our patients 
was 2.3 (1.9–2.6). Most patients were at interme-
diate risk (n = 37, 61%), 6 (10%) were in the low 
risk and 18 (29%) in the high risk group. Mortality 
rates after 48 months of high, intermediate and 
low risk groups were calculated as 68%, 32% and 
0%, respectively, as shown in Figure 1.
CVD risk factors and PAH severity
The PAH severity grade was found to correlate 
positively with age (R = 0.29, p = 0.02) and TG/
HDL-C ratio (R = 0.29, p = 0.02) and inversely with 
LDL-C (R = –0.28, p = 0.03) and HDL-C (R = –0.39, 
p = 0.02) concentrations. We found no association 
between PAH severity grade and BMI, TG or glu-
cose level (Figure 2).
Table II. Cardiovascular risk factors in males and females with idiopathic pulmonary arterial hypertension and age 
matched general population
Parameter IPAH (n = 61) Controls (n = 2413) P-value
Female  
(n = 40)
Male  
(n = 21)
Female  
(n = 1245)
Male  
(n = 1168)
Female Male
Age [years] 49.0 ±15.9 51.9 ±19.2 44.8 ±27.1 42.9 ±24.0 0.3 0.09
BMI [kg/m2] 25.0 ±3.5 25.3 ±4.4 25.9 ±7.3 27.1 ±6.7 0.4 0.2
SBP [mm Hg] 111.5 ±13.2 107.8 ±17.6 130.1 ±30.0 136.7 ±26.9 < 0.001 < 0.001
DBP [mm Hg] 72.5 ±8.6 69.5 ±11.1 80.6 ±13.1 82.4 ±15.7 < 0.001 < 0.001
LDL-C [mmol/l] 2.7 ±0.8 2.1 ±0.8 3.2 ±1.1 3.2±1.2 < 0.001 < 0.001
HDL-C [mmol/l] 1.3 ±0.4 1.1 ±0.4 1.4 ±0.4 1.2 ±0.5 0.03 0.4
TG [mmol/l] 1.3 ±0.7 1.4±0.7 1.1 ±0.8 1.6 ±1.6 0.2 0.1
TG/HDL-C 2.5 ±1.7 3.6 ±3.5 2.1 ±2.0 3.4 ±4.0 0.002 0.03
Glucose [mmol/l] 6.0 ±3.0 5.9 ±2.3 5.0 ±1.0 5.3±1.6 < 0.001 0.1
Diabetes (%) 20.0 9.5 5.9 4.6 0.001 0.6
Statin use (%) 25.0 38.1 11.9 11.2 0.03 < 0.001
Hypertension (%) 30.0 52.4 25 28.2 0.6 0.03
Active smoker (%) 7.5 0 27.1 35.6 < 0.001 –
BMI – body mass index, DBP – diastolic blood pressure, HDL-C – high-density lipoprotein cholesterol, IPAH – idiopathic pulmonary arterial 
hypertension, LDL-C – low-density lipoprotein cholesterol, SBP – systolic blood pressure, TG/HDL-C – triglyceride to high-density lipoprotein 
cholesterol ratio.
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Discussion
In our study we observed that IPAH males and 
females when compared to age-matched controls 
were characterized by lower LDL-C levels and an 
increased TG/HDL-C ratio. Female IPAH patients 
were also characterized by elevated fasting glu-
cose, higher prevalence of diabetes and a  lower 
HDL-C level. We also found that abnormal lipid 
profile correlated with pulmonary hypertension 
severity and that decreased levels of LDL-C and 
HDL-C, increased TG/HDL ratio and increased 
plasma glucose were associated with poor prog-
nosis. What is more, we implemented the recent-
ly proposed PAH severity grade in this group of 
patients.
The IPAH is a  disease with a  poor prognosis 
and accurate risk assessment is essential for 
appropriate management of patients [19–21]. 
Currently, the most commonly used approach is 
based on the ESC guidelines and includes assess-
ment of several markers of PAH severity such as 
patients’ symptoms, signs of right heart failure, 
exercise capacity, laboratory, hemodynamic and 
imaging parameters[1]. Kylhammar et al. [18] 
recently applied a new guideline-based method 
for risk assessment and validated it in 530 pa-
tients with PAH from the SPAHR registry [22]. In 
our study this score was also shown to accurately 
predict survival of the IPAH group. However, re-
cent data from large registries [18] underlined 
changing demographics among IPAH patients 
that also appeared to have a significant impact 
on patients’ prognosis. Increasing age of diagno-
sis and higher prevalence of co-morbidities re-
sulted in diminished response to treatment and 
worse survival. As shown in the recent reports, 
assessment of parameters reflecting metabolic 
status alongside the conventional disease risk 
markers was able to provide additional informa-
tion relevant in patients’ prognosis [5, 6, 10].
There is an expanding body of evidence that 
pulmonary hypertension is associated with alter-
ations in numerous metabolic pathways contribut-
ing to the disease onset and progression [3]. Recent 
studies suggest a role of altered function of bone 
morphogenic protein receptor type 2 (BMPR2) in 
development of metabolic abnormalities, and se-
verity of pulmonary vascular disease [23]. Mutation 
of BMPR2 is the most common cause of heritable 
PAH and its decreased signaling is also present in 
PAH of other etiologies [24]. Interestingly, altered 
BMPR2 function was also associated with obesi-
ty, dyslipidemia and metabolic syndrome [25–27]. 
Experimental studies also showed that metabolic 
alterations such as insulin resistance, low levels of 
plasma adiponectin as well as reduced expression 
of apolipoprotein E were able to induce PAH in an 
animal model. What is more, levels of circulating 
triglycerides and free fatty acids correlated with 
changes in pulmonary hemodynamics and degree 
of pulmonary artery remodeling in fat-fed animals, 
highlighting the role of metabolic alterations in 
PAH progression [28]. 
The latest clinical studies also suggest an im-
portant role of CVD risk factors including HDL-C 
and TG/HDL-C in prognosis of PAH patients [5, 
29–32]. Heresi et al. observed that PAH patients 
were characterized by decreased HDL-C levels 
which were associated with higher mortality inde-
pendently of disease severity, age and sex of pa-
tients [5]. The vasoprotective function of HDL-C in 
the pulmonary circulation was further explained 
by its abilities to mitigate inflammation and en-
hance prostacyclin half-life. Both decreased HDL-C 
and elevated TG in the general population have 
also been associated with features of metabolic 
syndrome and insulin resistance [33–35]. The TG/
HDL-C ratio was previously established as a sim-
ple parameter able to identify insulin resistant in-
dividuals with better predictive value than other 
single or combined lipid fractions.
Numerous studies have confirmed that inflam-
matory cytokines can both increase TG and de-
crease HDL-C levels and in consequence elevate 
the TG/HDL-C ratio [36]. We have also shown that 
interleukin 1β, interleukin 6 and high-sensitivity 
C-reactive protein correlate with the level of HDL-C 
[37]. What is more, TG/HDL-C was recently pro-
posed as a novel risk factor in PAH patients [6]. Our 
results, similarly to observations in the PAH pop-
ulation, indicate that TG/HDL-C ratio was able to 
predict worse prognosis and increased mortality.
In the present study we demonstrated that pa-
tients with IPAH are characterized by lower LDL-C, 
which is associated with increased mortality. Re-
cent studies also underlined the association be-
tween LDL-C level and prognosis in PAH [10]. Ele-
vated LDL-C is a well-established CVD risk factor 
in the general population, but in some chronic dis-
eases including rheumatoid arthritis, heart failure 
and chronic kidney disease low LDL-C levels pre-
 Low risk (n = 6, 0 deaths)
 Intermediates risk (n = 37, 14 deaths)
 High risk (n = 18, 14 deaths)
Figure 1. Survival curves of patients in high, inter-
mediate and low risk group
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dicted poor prognosis [38]. This manifestation of 
reverse epidemiology was assigned to abnormal 
cytokine and neurohormonal secretion, resulting 
in some groups of patients in cardiac cachexia and 
increased mortality [11]. We recently demonstrat-
ed that patients with PAH and chronic thrombo-
embolic pulmonary hypertension (CTEPH) have 
lower LDL-C levels compared to healthy controls 
and its concentration showed a strong linear re-
lationship with risk of all-cause mortality [10]. In-
terestingly, improvement of hemodynamic param-
eters after treatment of CTEPH led to reversal of 
decreased levels of LDL-C. The observed findings 
were explained by the fact that lipids and lipopro-
teins can modulate inflammation, which has been 
associated with progression of pulmonary vas-
cular disease, although the exact mechanism of 
observed changes still remains unknown [39–41]. 
We found that a  significant number of study 
patients were using statins when they were first 
evaluated in our center. This could have resulted 
from the presence of comorbid conditions or pre-
vious misdiagnosis. Recent studies have shown 
that diagnosis of PAH may be challenging. Strange 
et al. demonstrated that correct PAH diagnosis 
takes 47 ±34 months. Patients report 5.3 ±3.8 
general physician visits and 3.0 ±2.1 specialist 
reviews before being seen at a pulmonary hyper-
tension center. Before the final diagnosis of PAH 
they have approximately two false diagnoses such 
as ischemic heart disease, heart failure or pulmo-
nary disease [42]. These misdiagnoses might have 
contributed at least partly to the high number of 
patients using statins during first assessment in 
our center. What is more, according to data from 
large PAH registries [43], comorbid conditions in 
this population are becoming more frequent in re-
cent years. Prevalence of coronary artery disease 
in PAH patients increased from 7% to 16% be-
tween the years 2001 and 2009. Similarly, in our 
study 15% of patients (and 29% of male patients) 
had a previously established diagnosis of coronary 
artery disease. This may explain the high frequen-
cy of statin treatment, especially in male subjects.
In the current study we also demonstrated that 
changes in glucose metabolism may affect progno-
sis in IPAH patients. Diabetes and elevated fasting 
glucose were more common in IPAH females than 
in their counterparts in the general population. 
Similarly, recent clinical studies confirmed that 
patients with pulmonary hypertension are char-
acterized by glucose intolerance, pancreatic β-cell 
dysfunction and elevated hemoglobin A
1c [9]. The 
exact pathophysiological link between changed 
metabolism of glucose and prognosis in IPAH is 
unknown; however, both clinical and experimental 
data indicate that chronic inflammation plays an 
important role in glucose homeostasis and severi-
ty of pulmonary vascular disease [2]. Higher prev-
alence of diabetes in women with IPAH than in 
their age-matched counterparts from the general 
population is a novel finding but corresponds with 
the results of another study which showed an in-
creased prevalence of insulin resistance in PAH 
females [6]. The association between female sex 
and abnormalities of glucose metabolism in PAH 
has not been well established but experimental 
data suggest a role of estrogen metabolism [44].
The alterations in lipid and glucose metabolism 
are often ascribed to obesity. In our study we how-
ever did not find differences in BMI between IPAH 
patients and age-matched controls. What is more, 
BMI was not associated with disease severity or 
increased mortality in the IPAH population. The 
association between obesity and prognosis in pul-
monary hypertension is still not clear. Data from 
the REVEAL registry showed that PAH patients are 
characterized by similar BMI as the control popu-
lation. Obese patients were older, and had higher 
prevalence of CVD risk factors including diabetes 
and hypertension. Interestingly, this group was 
also characterized by more severe disease with 
higher WHO-FC, right atrial pressure, pulmonary 
vascular resistance and lower cardiac index [45]. 
Other studies suggest that in PAH patients, simi-
larly to other populations with severe chronic dis-
eases, obesity is associated with improved surviv-
al [11]. This finding was further explained by the 
phenomenon known as the “obesity paradox,” 
indicating a prognostic role of abnormal cytokine 
secretion and cardiac cachexia. This may suggest 
that the association between obesity and progno-
sis in pulmonary hypertension may be more com-
plex and dependent on chronic inflammation and 
other obesity-related risk factors [46, 47]. 
Strengths and limitations
Our study has several strengths. First, the find-
ings are novel since the prognostic values of CVD 
risk factors in IPAH patients are hardly known. In 
contrast to most previous studies we analyzed 
a homogeneous group of patients with IPAH. This 
is a specific group of patients in whom secondary 
causes of pulmonary hypertension including con-
genital heart disease, connective tissue disease, 
HIV infection and hepatic cirrhosis have been ex-
cluded. All of the diseases can significantly influ-
ence the prevalence of CVD and their clinical rel-
evance. Second, the follow-up time in our study 
was longer than that used in most similar studies. 
Third, our study has important clinical implications. 
It describes a  metabolic profile of patients with 
IPAH which is different than in the general pop-
ulation and may have a  different clinical impact. 
It also indicates new prognostic factors that may 
be helpful when assessing the risk of death in in-
dividual patients with IPAH. Finally, our study im-
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plemented for the first time the recently proposed 
method of risk assessment in Polish IPAH patients. 
We acknowledge that our study also has limita-
tions, due to the single-center design and limited 
sample size, and the number of events we needed 
to limit adjustment of our regression models only 
for selected variables (age or age and sex or PAH 
severity grade). We were however able to include 
in the modeling a score of PAH severity which in-
tegrates several aspects of PAH risk markers. Fur-
ther multicenter studies may be needed to con-
firm our findings in different populations. Second, 
an important number of IPAH patients were taking 
statins and/or had diabetes, which may influence 
the LDL-C level and TG/HDL-C ratio, respectively. 
However, when we excluded patients who used 
statins or patients who had diabetes, still IPAH 
patients had a lower LDL-C level or increased TG/
HDL-C ratio than observed in the general popula-
tion. Additionally, we did not find evidence for an 
association between statin use or the diagnosis 
of diabetes and mortality in our group. Third, we 
only assessed the level of HDL-C without investi-
gating its structure and function. It is well known 
that inflammation can also alter the structure and 
function of HDL-C particles, enabling progression 
of vascular disease. During conditions associated 
with oxidative stress, inflammation and hyper-
glycemia, HDL-C may undergo post-transitional 
changes that affect their vasoprotective proper-
ties. This altered HDL-C can then exacerbate the 
inflammatory response and is often referred to as 
dysfunctional HDL-C [32]. Finally, in the present 
study we cannot determine exact mechanisms of 
the observed findings. We were however able to 
propose potential mechanisms based on similar 
observations in different populations and in an 
experimental setting.
In conclusion, patients with IPAH are charac-
terized by an altered profile of lipid and glucose 
metabolism. Lowered levels of LDL-C and HDL-C 
and increased TG/HDL-C ratio correlate with dis-
ease severity and together with elevated plasma 
glucose level predict poor survival in IPAH.
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